Table of Contents
Overview
New York, NY – Sep 23, 2025 –The Global Preimplantation Genetic Testing Market size is expected to be worth around USD 1648.6 Million by 2033 from USD 817.9 Million in 2024, growing at a CAGR of 8.1% during the forecast period from 2025 to 2033.
Preimplantation Genetic Testing (PGT) has emerged as a transformative technique in reproductive medicine, offering couples the opportunity to reduce the risk of passing on genetic disorders and to improve the chances of successful pregnancies. This procedure is carried out during in vitro fertilization (IVF), where embryos are screened before implantation to identify chromosomal abnormalities or specific genetic mutations.
PGT plays a significant role in enhancing clinical outcomes by allowing the transfer of embryos with the highest likelihood of developing into a healthy pregnancy. The testing can detect conditions such as Down syndrome, cystic fibrosis, and thalassemia, among others. By identifying genetic issues early, it helps in minimizing the chances of miscarriage and improving live birth rates.
The demand for PGT is increasing globally due to the rising prevalence of genetic disorders, delayed pregnancies, and growing awareness among patients and healthcare professionals. Technological advancements in next-generation sequencing (NGS) and other molecular diagnostic methods have further improved the accuracy and efficiency of the testing process.
Clinics and fertility centers worldwide are integrating PGT into their IVF programs, highlighting its importance in personalized reproductive care. As healthcare systems continue to embrace innovation, PGT is expected to play a crucial role in shaping the future of assisted reproduction by combining scientific precision with patient-centered solutions.
Key Takeaways
- Market Size and Growth: The global Preimplantation Genetic Testing (PGT) market was valued at USD 756.6 million in 2023 and is projected to reach approximately USD 1,648.6 million by 2033, expanding at a compound annual growth rate (CAGR) of 8.1%.
- By Procedure Type: Preimplantation Genetic Diagnosis (PGD) accounted for the largest share in 2023, representing nearly 78% of total market revenue.
- By Product Type: Reagents and consumables dominated the product landscape, contributing 50.6% of total revenue in 2023.
- By Technology: Polymerase Chain Reaction (PCR) remained the leading technology segment, generating 40.6% of market revenue in 2023.
- By Application: Aneuploidy screening emerged as the most prominent application, holding 26.8% of the total market share in 2023.
- By End-User: Hospitals represented the largest end-user segment, accounting for approximately 40% of the market revenue in 2023.
- Regional Analysis: North America led the global market with a 36.4% revenue share in 2023, equivalent to USD 275.4 million.
Regional Analysis
North America emerged as the leading region in the global preimplantation genetic diagnosis (PGD) market in 2023, capturing 36.4% of the overall share and contributing USD 275.4 million in revenue. The region’s strong position can be attributed to rising healthcare expenditures, advanced medical infrastructure, and a steadily expanding patient base seeking fertility solutions. Increasing awareness of genetic testing, coupled with supportive healthcare policies, has further accelerated the adoption of PGD across the region.
Within North America, states such as Massachusetts, Columbia, and New Jersey have demonstrated particularly high rates of births achieved through assisted reproductive technologies (ART). This trend highlights the region’s active involvement in the field and reflects its significant success in applying PGD solutions to improve reproductive outcomes. With continued investments in research and clinical practices, North America is expected to maintain its dominant role in driving innovation and growth in the PGD market.
Frequently Asked Questions on Preimplantation Genetic Testing
- What is Preimplantation Genetic Testing (PGT)?
Preimplantation Genetic Testing (PGT) is a laboratory procedure performed during in vitro fertilization (IVF) to analyze embryos for chromosomal abnormalities or genetic mutations before implantation, helping to select healthy embryos and reduce risks of genetic disorders. - Why is PGT important in reproductive medicine?
PGT is important because it enhances the chances of a successful pregnancy by identifying embryos without genetic abnormalities. It also reduces the risk of miscarriage and genetic disease transmission, providing couples with improved reproductive outcomes and healthier live births. - What conditions can PGT detect?
PGT can detect a wide range of genetic conditions, including aneuploidy (chromosomal abnormalities like Down syndrome), single-gene disorders such as cystic fibrosis, sickle cell anemia, and thalassemia, as well as chromosomal rearrangements linked to infertility or recurrent pregnancy loss. - What is the future outlook for the PGT market?
The PGT market is expected to witness sustained growth due to increasing acceptance of fertility treatments, personalized reproductive care, and continuous technological innovation. Expanding awareness in developing economies will further boost global adoption and create new growth opportunities. - Who should consider PGT?
PGT is recommended for couples with a family history of genetic diseases, women of advanced maternal age, individuals with repeated pregnancy loss, or patients undergoing multiple failed IVF cycles. It is also advised for carriers of known genetic mutations. - Is PGT safe for embryos?
PGT is generally considered safe when performed by skilled professionals. The biopsy involves removing a few cells from the embryo without affecting its overall development, and advances in technology have further minimized potential risks to embryo viability. - Which segment holds the largest share in the PGT market?
In 2023, Preimplantation Genetic Diagnosis (PGD) accounted for nearly 78% of global revenue share. Additionally, reagents and consumables represented 50.6% of product sales, highlighting their critical role in routine testing and laboratory workflows supporting fertility clinics. - Which region dominates the PGT market?
North America dominates the global PGT market with a 36.4% revenue share in 2023, contributing USD 275.4 million. The region’s leadership stems from advanced healthcare infrastructure, high healthcare expenditures, and widespread adoption of assisted reproductive technologies.
Conclusion
In conclusion, Preimplantation Genetic Testing (PGT) is transforming reproductive medicine by improving pregnancy success rates and reducing the risk of genetic disorders. Supported by advanced technologies such as PCR and next-generation sequencing, PGT ensures greater accuracy and efficiency in embryo selection.
The market shows strong growth potential, projected to nearly double by 2033 with a CAGR of 8.1%. North America continues to lead the industry due to robust healthcare infrastructure, rising expenditure, and high adoption of assisted reproductive technologies. With increasing global awareness, PGT is expected to remain integral to personalized reproductive care and future fertility advancements.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
